Glatiramer

Literature References: Random basic synthetic copolymer of L-alanine, L-lysine, L-glutamic acid and L-tyrosine in a molar ratio of 6:1.9:4.7:1. Mol wt of 14,000 to 23,000 Da. Immunologically cross reactive with myelin basic protein. Prepn: D. Teitelbaum et al., Eur. J. Immunol. 1, 242 (1971). Suppression of exptl. allergic encephalomyelitis (EAE): eidem, ibid. 3, 273 (1973). Inhibition of T-cell response to myelin basic protein: D. Teitelbaum et al., Proc. Natl. Acad. Sci. USA 89, 137 (1992); of binding to major histocompatibility complex: M. Fridkis-Hareli et al., ibid. 91, 4872 (1994). Clinical trials in multiple sclerosis: M. B. Bornstein et al., Neurology 41, 533 (1991); K. P. Johnson et al., ibid. 45, 1268 (1995). Review of pharmacology and early clinical evaluation: L. A. Rolak, Clin. Neuropharmacol. 10, 389 (1987); suppression of EAE: R. Arnon, Israel J. Med. Sci. 25, 686-689 (1989).